1月21日，东宝生物涨5.06%，截至发稿，报6.44元/股，成交1.42亿元，换手率3.83%，总市值38.23亿 元。 资料显示，包头东宝生物技术股份有限公司位于内蒙古自治区包头市稀土高新技术产业开发区黄河大街 46号，成立日期1997年3月12日，上市日期2011年7月6日，公司主营业务涉及明胶系列产品及小分子量 胶原蛋白的研发、生产、销售。主营业务收入构成为：胶囊业务54.13%，明胶系列产品及副产品磷酸 氢钙37.30%，胶原蛋白业务7.81%，有机肥业务0.53%，其他(补充)0.22%。 广发聚丰混合A（270005）成立日期2005年12月23日，最新规模33.66亿。今年以来收益11.92%，同类 排名540/8844；近一年收益70.13%，同类排名640/8091；成立以来收益556.36%。 广发聚丰混合A（270005）基金经理为苏文杰。 截至发稿，苏文杰累计任职时间7年93天，现任基金资产总规模97.34亿元，任职期间最佳基金回报 167.69%， 任职期间最差基金回报5.18%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股 ...

Group 1 - The core point of the article highlights the recent performance of Dongbao Bio, with a stock price increase of 5.13% to 6.15 CNY per share, a trading volume of 97.52 million CNY, a turnover rate of 2.77%, and a total market capitalization of 3.651 billion CNY [1] - Dongbao Bio, established on March 12, 1997, and listed on July 6, 2011, is located in Baotou, Inner Mongolia, and specializes in the research, production, and sales of gelatin products and low molecular weight collagen [1] - The main business revenue composition of Dongbao Bio includes capsule business at 54.13%, gelatin series products and by-products at 37.30%, collagen business at 7.81%, organic fertilizer business at 0.53%, and other supplementary products at 0.22% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guangfa Fund has a fund that ranks among Dongbao Bio's top ten circulating shareholders, specifically Guangfa Jufeng Mixed A (270005), which entered the top ten in the third quarter with 4.5228 million shares, accounting for 0.77% of circulating shares [2] - Guangfa Jufeng Mixed A (270005) was established on December 23, 2005, with a latest scale of 3.366 billion CNY, and has achieved a year-to-date return of 1.2%, ranking 5853 out of 8816 in its category, and a one-year return of 59.59%, ranking 1201 out of 8081 [2]

Group 1 - Dongbao Biological experienced a stock price increase of 7.04%, reaching 5.93 CNY per share, with a trading volume of 87.45 million CNY and a turnover rate of 2.63%, resulting in a total market capitalization of 3.52 billion CNY [1] - The company, founded on March 12, 1997, and listed on July 6, 2011, is located in Baotou, Inner Mongolia, and specializes in the research, production, and sales of gelatin products and low molecular weight collagen [1] - The main revenue composition of Dongbao Biological includes capsule business (54.13%), gelatin products and by-products (37.30%), collagen business (7.81%), organic fertilizer (0.53%), and others (0.22%) [1] Group 2 - Among the top ten circulating shareholders of Dongbao Biological, one fund from GF Fund Management, GF Jufeng Mixed A (270005), entered the list in the third quarter, holding 4.52 million shares, which accounts for 0.77% of the circulating shares [2] - The estimated floating profit for GF Jufeng Mixed A today is approximately 1.76 million CNY [2] - GF Jufeng Mixed A was established on December 23, 2005, with a current scale of 3.37 billion CNY, and has achieved a year-to-date return of 30.78%, ranking 1994 out of 8136 in its category [2]

Core Viewpoint - Dongbao Biological is a leading gelatin and collagen producer in China, with significant technological barriers and a notable market share in the industry [1] Group 1: Business Overview - Dongbao Biological was established on March 12, 1997, and listed on the Shenzhen Stock Exchange on July 6, 2011, with its registered and operational base in Baotou, Inner Mongolia [1] - The company's main business includes the research, production, and sales of gelatin products and low molecular weight collagen, categorized under the pharmaceutical and biological industry [1] Group 2: Financial Performance - For Q3 2025, Dongbao Biological reported revenue of 533 million yuan, ranking 22nd among 34 companies in the industry, with the industry leader, Changchun High-tech, generating 9.807 billion yuan [2] - The net profit for the same period was 48.447 million yuan, placing the company 20th in the industry, while the top performer, Tonghua Dongbao, achieved a net profit of 1.188 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Dongbao Biological's debt-to-asset ratio was 32.50%, higher than the industry average of 26.88% and improved from 36.68% in the previous year [3] - The company's gross profit margin was 24.53%, an increase from 22.62% year-on-year, but still below the industry average of 70.17% [3] Group 4: Executive Compensation - The chairman, Wang Aiguo, received a salary of 9,600 yuan for 2024, unchanged from the previous year, while the general manager, Liu Fang, earned 745,100 yuan, a decrease of 32,000 yuan from 2023 [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.01% to 20,500, while the average number of circulating A-shares held per shareholder increased by 6.39% to 28,800 [5]

Investment Rating - The investment rating for the company is "Outperform" [1] Core Views - The company is expected to see significant profit growth in 2024, with a projected net profit of 676 million yuan, representing a year-on-year increase of 45.2% [5] - The company plans to initiate a listing process on the Hong Kong Stock Exchange to enhance its global strategic layout [5] - The company has experienced a decline in profit margins despite an increase in sales volume for modified plastics and composite materials [5] Financial Data and Profit Forecast - Total revenue for 2024 is projected at 19.22 billion yuan, with a year-on-year growth rate of 10.2% [4] - The net profit for 2025 is estimated at 706 million yuan, with an expected growth rate of 4.4% [4] - Earnings per share (EPS) are forecasted to be 2.60 yuan for 2025, 3.45 yuan for 2026, and 3.94 yuan for 2027 [5][4] Sales Performance - In 2024, the company achieved sales of 1.0632 million tons of organic polymer modified materials, a year-on-year increase of 7% [5] - The sales volume of organic polymer composite materials reached 349,600 tons in 2024, reflecting a year-on-year growth of 23% [5] - The company has made advancements in the development of composite materials for the new energy sector, including breakthroughs in lightweight materials for eVTOL structures [5] Strategic Acquisitions - The company acquired 99.99% of Hong Kong Petrochemical and 67% of Guoen Dongming, enhancing its integrated advantages in the industry [5] - The acquisition of these assets is expected to significantly contribute to the company's production capacity and revenue growth in the future [5] Health Industry Performance - The health sector subsidiary, Dongbao Biological, reported a net profit of 86 million yuan in 2024, a decrease of 28% year-on-year due to price reductions in downstream pharmaceuticals [5] - The company is expanding its production capacity in the health sector, with plans to increase capsule production significantly [5]